From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

The billion dollar fraud Tingo – the weakest rebuttal in history & an explicit warning for US investors from Tingo itself

By Tom Winnifrith | Wednesday 7 June 2023


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Yesterday, bear raiders Hindenburg weighed into the battle with Tingo (US:TIO), the billion dollar fraud masterminded by Chris Cleverly, the cousin of foreign secretary James. The dossier HERE showed that Tingo’s claimed operations either did not exist or had a skeletal presence which shows that its claimed revenues and profits are just bogus as, almost certainly, is its claimed cash. Tingo has responded with what Lucian Miers calls “one of the most feeblest rebuttals I have seen ( and I have seen a lot)”. Meanwhile Tingo itself has a warning for American investors.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:


Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:40:56